According to a recent study, low-dose oral bisphosphonates administered to prevent or treat postmenopausal osteoporosis may be associated with a lower risk of skeletal metastasis in patients with early- or more advanced-stage breast cancer.
According to a recent study, low-dose oral bisphosphonates administered to prevent or treat postmenopausal osteoporosis may be associated with a lower risk of skeletal metastasis in patients with early- or more advanced-stage breast cancer.
The findings are based on analysis of health administrative data from a historical cohort of 21,664 women diagnosed with breast cancer in Quebec, Canada. Researchers from McGill University Health Centre stratified the cohort according to disease stage (0-II or III) at time of diagnosis. The primary outcome was time to development of bone metastasis. Exposure was considered bisphosphonate use prediagnosis, postdiagnosis, both, or neither, and a cumulative index of drug exposure.
In women with local disease at diagnosis, use of bisphosphonates only postdiagnosis or continuing on them after breast cancer diagnosis was associated with a decline in risk of bone metastasis from 45% to 28%. The reduction in risk associated with bisphosphonates was nearly 50% in women with regional disease who used the drugs postdiagnosis, regardless of whether they had used bisphosphonates prediagnosis.
Researchers also observed a statistically significant dose-response trend that related increased use with lower risk (slope = 0.94, 95% confidence interval = 0.90 to 0.99). Also, bisphosphonates were associated with a decreased risk of all-cause mortality similar to that for development of bone metastasis.
Editorial: Graduate medical education at crossroads
Investigators concluded that low-dose bisphosphonates used for the prevention or treatment of postmenopausal osteoporosis were tied to lower risk of skeletal metastasis in patients with early- and advanced-stage breast cancer.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More